Everything below concerns responder analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
Narcotics in Bolivia, South America, is a subject that primarily involves the coca crop, used in the production of the drug, cocaine. Trafficking and corruption have been two of the most prominent negative side-effects of the illicit narcotics trade in Bolivia and the country's government has engaged in negotiations with the United States (US) as result of the industry's ramifications.
Laboratory equipment refers to the various tools and equipment used by scientists working in a laboratory. Laboratory equipment is generally used to either perform an experiment or to take measurements and gather data. Larger or more sophisticated equipment is generally called a scientific instrument. The classical equipment includes tools such as Bunsen burners and microscopes as well as specialty equipment such as operant conditioning chambers, bioreactors, hematology analyzers, autoclaves, centrifuges, spectrophotometers and calorimeters, glucometer, incubator.
== Indications == There are no clinical guidelines outlining the use and implementation of opioid rotation. However, this strategy is commonly used for these various situations: pain not controlled by current opioid, pain controlled but in the presence of intolerable adverse events, pain not controlled despite rapid increase in opioid dose, switching to utilize different alternative routes of administration, or switching due to high cost of current opioid (or other patient-specific cost considerations).
Methaqualone was manufactured in the United States under the name Quaalude by the pharmaceutical firms Rorer and Lemmon with the numbers 714 stamped on the tablet, so people often referred to Quaalude as 714's, "Lemmons", or "Lemmon 7's". Methaqualone was also manufactured in the US under the trade names Sopor and Parest. After the legal manufacture of the drug ended in the United States in 1982, underground laboratories in Mexico continued the illegal manufacture of methaqualone throughout the 1980s, continuing the use of the "714" stamp, until their popularity waned in the early 1990s. Drugs purported to be methaqualone are in a significant majority of cases found to be inert, or contain diphenhydramine or benzodiazepines. Illicit methaqualone is one of the most commonly used recreational drugs in South Africa. Manufactured clandestinely, often in India, it comes in tablet form, but is smoked with marijuana. This method of ingestion is known as "white pipe". It is popular elsewhere in Africa and in India.
increasing insulin sensitivity reducing hyperandrogenism reducing the risk of metabolic disease restoring follicle-stimulating hormone (FSH) to luteinizing hormone (LH) ratio and menstrual cycle regularization increasing the chance of success in patients seeking reproductive therapy Combination therapy with myo-inositol (MI) and D-chiro-inositol (DCI) has also been extensively clinically explored, with the balance of each stereroisomer in circulation gaining popularity as a clinical target. Insulin stimulates the irreversible conversion of MI to DCI by an NADPH-dependent epimerase, and both hyperinsulinemia and elevated DCI are clinically evident in 70% of PMOS patients. The plasmatic ratio of MI and DCI in healthy subjects is 40:1 MI to DCI respectively, and using this ratio as a clinical target shows the same efficacy of MI alone but in a shorter time. In addition, the physiological ratio maintains healthy oocyte quality in patients using DCI for fertility therapy, whereas DCI monotherapy is known to impair oocyte quality. Disturbances in intracellular MI and DCI ratios are linked to an "inositol resistance" phenotype, where MI monotherapy is less effective. MI and α-lactalbumin combination therapy increases myo-inositol plasmatic content in inositol-resistant patients with a relative improvement of hormonal and metabolic parameters.
Sources: en.wikipedia.org
== Atrial fibrillation == Pulmonary vein isolation has been the mainstay of atrial fibrillation reduction, but in many cases there are other sources of arrhythmia, including the LoM. Use of ethanol through the VoM has been shown to be an effective way to reduce atrial fibrillation.
As nitrogen is an asphyxiant gas in itself, some jurisdictions have considered asphyxiation by inhalation of pure nitrogen as a means of capital punishment (as a substitute for lethal injection). In January 2024, Kenneth Eugene Smith became the first person executed by nitrogen asphyxiation.
The Grand Lodge, being only responsible for the first three degrees, does not represent all of Cuban Freemasonry without the Supreme Council, which is responsible for all the higher degrees, from the 4th to the 33rd degrees. Cuban Freemasons considered this as an insult to the Supreme Council, and an attempt to reject the Grand Commander's authority. Cuban Freemasons sent a flood of calls, emails, and letters to the office of Grand Master Zamora Fernández to refuse to meet with the President. On August 23, Zamora Fernández wrote a letter distributed to Cuban Freemasons indicating that the office of the Grand Master had decided not to attend the meeting "...in order to preserve Masonic unity". The Freemason and Cuban activist writer Ángel Santiesteban Prats stated that President Díaz-Canel's full intention was to completely fracture Freemasonry in Cuba. Santiesteban said: "I doth my hat to the Grand Master's wise decision. Masonic unity above all. History is being made... it is a milestone in our country's history, especially over the last 62 years. I remind you that Freemasonry is the only institution in Cuba that didn't dance like puppets on the stage with Fidel Castro and demand the return of that boy Elián. Everybody else gave in. The Abakuás, the spiritists, and the Yoruba Association, they all caved to Castro." On March 28, 2022, Grand Treasurer Francisco Javier Alfonso Vidal was elected as Grand Master of the Grand Lodge of Cuba.
Dr. George D. Winter (1927–1981) was the British-born pioneer of moist wound healing. In 1962, while working at the Department of Biomechanics and Surgical Materials at the University of London, Winter published his landmark Nature paper Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig (Nature 193:293 1962) where he demonstrated that, contrary to the conventional wisdom that wounds should be allowed to dry out and form scabs to promote healing, wounds instead healed faster if kept moist. Winter formed multiple partial thickness wounds on the backs of pigs, half left open to the air and half covered with a polymer film to keep them hydrated. The latter wounds healed faster, as measured by the migration of new epithelium on the wound bed. This work began the evolution of modern wound dressings that promote moist wound healing. George D. Winter was the first president of the European Society for Biomaterials and has an annual award named after him.
For example, in an invited address to the Indian parliament in December 2010, Jagdish Bhagwati, Professor of Economics and Law at the Columbia University analysed the relationship between growth and poverty reduction, then urged the Indian parliament to extend economic reforms by freeing up of the retail sector, further liberalisation of trade in all sectors, and introducing labour market reforms. Such reforms Professor Bhagwati argued will accelerate economic growth and make a sustainable difference in the life of India's poorest., A 2007 report noted that an increasing number of people in India are turning to the services sector for employment due to the relative low compensation offered by the traditional agriculture and manufacturing sectors. The organised retail market is growing at 35 percent annually while growth of unorganised retail sector is pegged at 6 percent. The Retail Business in India is currently at the point of inflection. As of 2008, rapid change with investments to the tune of US$25 billion were being planned by several Indian and multinational companies in the next 5 years. It is a huge industry in terms of size and according to India Brand Equity Foundation (IBEF), it is valued at about US$395.96 billion. Organised retail is expected to garner about 16-18 percent of the total retail market (US$65–75 billion) in the next 5 years. India has topped the A.T. Kearney's annual Global Retail Development Index (GRDI) for the third consecutive year, maintaining its position as the most attractive market for retail investment.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.